What's Next—Amylin-based Therapies

We are entering an era of choice in terms of diabetes and obesity therapies. Choice is good, but having a keen understanding of each medication is crucial to avoid being overwhelmed. In this special episode of DOC Updates , host Dr. Neil Skolnik explores the latest amylin-based therapies. This special episode is sponsored with support from Novo Nordisk . Presented by: Neil Skolnik , MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Juan Pablo Frias , MD, Medical Director and Principal Investigator, Los Angeles Institute for Metabolic Research, Adjunct Professor of Medicine at Charles Drew University of Medicine and Science Selected References: Garvey, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity," N Engl J Med 2025;393:635-647 doi.org/10.1056/NEJMoa2502081 Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study," The Lancet Diabetes & Endocrinology, 2026; 14, 649-661 doi.org/10.1016/S2213-8587(26)00126-9